Premium
In Brief: Myeloid‐derived suppressor cells in cancer
Author(s) -
Solito S,
Pinton L,
Mandruzzato S
Publication year - 2017
Publication title -
the journal of pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.964
H-Index - 184
eISSN - 1096-9896
pISSN - 0022-3417
DOI - 10.1002/path.4876
Subject(s) - myeloid derived suppressor cell , angiogenesis , suppressor , cancer , cancer research , medicine , promotion (chess) , immunology , political science , politics , law
The role of myeloid‐derived suppressor cells ( MDSCs ) in cancer development has become clear over recent years, and MDSC targeting is an emerging opportunity for enhancing the effectiveness of current anticancer therapies. As MDSCs are not only able to limit anti‐tumour T‐cell responses, but also to promote tumour angiogenesis and invasion, their monitoring has prognostic and predictive value. Herein, we review the key features of MDSCs in cancer promotion. © 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.